Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company focused on developing innovative therapies for rare diseases. The company recently received a significant boost when Evercore ISI updated its rating for ASND to "Outperform" on March 2, 2026. At the time, the stock was priced at approximately $233, with a new price target set at $324, as highlighted by StreetInsider.
The positive outlook for Ascendis Pharma is largely driven by the FDA's approval of Yuviwel, a groundbreaking treatment for children with achondroplasia. This once-weekly therapy, also known as navepegritide, is the first of its kind designed to enhance linear growth in children aged two years and older. The approval was based on data from three randomized clinical trials, marking a significant advancement in treatment options for this rare genetic disorder.
Yuviwel's approval under the FDA's Accelerated Approval Program is a major milestone for Ascendis Pharma. The therapy provides continuous systemic exposure to CNP over a weekly dosing interval, with improvements in annualized growth velocity (AGV) being a key factor in its approval. The company has also been granted a Rare Pediatric Disease Priority Review Voucher, further underscoring the therapy's importance.
Ascendis Pharma plans to make Yuviwel available through prescribing physicians in the United States by early in the second quarter of 2026. The stock's current price is $233.01, reflecting a slight decrease of 0.21% or $0.49, with a market capitalization of approximately $14.3 billion.
ASND's stock has fluctuated between a low of $232.59 and a high of $234.73 today, with a 52-week high of $242 and a low of $124.06. The trading volume for ASND is 602,078 shares, indicating strong investor interest. The FDA approval and Evercore ISI's updated rating are expected to positively impact the stock's performance in the coming months.
